Beauty Health’s latest narrative update features a slightly higher price target, with fair value steady at about $1.93 per share while the discount rate nudges up to reflect a bit more perceived risk. Expectations for annual revenue growth remain close to 4.0% as analysts weigh improving execution against ongoing uncertainties around the pace of the turnaround. Read on to see what is driving this cautious optimism and how you can stay ahead of future shifts in the story.
Stay updated as the Fair Value for Beauty Health shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Beauty Health.
🐂 Bullish Takeaways
-
TD Cowen analyst Oliver Chen lifted his price target on Beauty Health to $2.50 from $2.00, signaling modest upside from the current fair value of about $1.93 per share.
-
Chen credits the CEO reset with improving execution, pointing to better management of device sales churn (roughly 30% of the model) and stronger consumables innovation (about 70%) as key drivers for a more constructive stance.
-
Deeper engagement across the roughly 35k installed provider base is viewed as a positive indicator for sustaining revenue growth and supporting the stock’s rerating potential if progress continues.
🐻 Bearish Takeaways
-
Despite the higher target, TD Cowen maintains a Hold rating, underscoring that near-term risks and execution uncertainty remain, with much of the perceived improvement arguably already reflected in the current valuation.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
-
Beauty Health appointed Pedro Malha as Chief Executive Officer, effective October 1, 2025, with outgoing CEO Marla Beck moving into an advisory role after overseeing a multiyear operational and innovation reset.
-
The company reaffirmed its 2025 earnings guidance, projecting net sales of $293M to $300M, reinforcing expectations for continued top line stabilization and moderate growth.
-
Management reported progress on capital return, completing repurchases of 10,350,749 shares, or 7.81% of shares outstanding, for $30.18M under its buyback program announced on September 12, 2023.
-
No additional shares were repurchased in the July 1 to September 30, 2025 period, indicating a pause in buyback activity as the company balances liquidity, leverage, and investment in the turnaround.
-
Fair Value: Unchanged at approximately $1.93 per share, indicating no revision to intrinsic value estimates in the latest update.
-
Discount Rate: Risen slightly from about 11.73% to 11.84%, reflecting a modestly higher perceived risk or cost of capital embedded in the model.
-
Revenue Growth: Effectively unchanged at roughly 4.0% annually, signaling stable expectations for top line expansion.
-
Net Profit Margin: Essentially flat at about 5.46%, suggesting no material shift in long term profitability assumptions.
-
Future P/E: Edged up slightly from around 19.50x to 19.56x, which points to a marginally higher valuation multiple applied to forward earnings.
Narratives are the story behind the numbers, connecting a company’s real world drivers to a clear financial forecast and fair value. On Simply Wall St’s Community page, millions of investors use Narratives to turn views on revenue, earnings, and margins into a live estimate of fair value, then compare it to the current price to decide when to buy or sell. As news, earnings, and guidance change, Narratives update dynamically so your investment view stays current and actionable.
Head over to the Simply Wall St Community and follow the Narrative on Beauty Health to stay on top of the moving parts that drive its value:
-
How managing device churn across 35,000+ installed systems shapes recurring consumables revenue and long term growth.
-
Whether premium Hydrafacial demand, global expansion, and innovation can offset macro, regulatory, and competitive pressures.
-
How the analyst consensus on revenue, margins, and a future P/E near 19.6x ties to a fair value of about $1.93 versus today’s price.
Read the full Beauty Health Narrative on Simply Wall St to see how the story, forecasts, and fair value connect in one place.
Curious how numbers become stories that shape markets? Explore Community Narratives
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SKIN.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
